亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台，協助業界發掘知識產權貿易商機，並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權，或是製造商需要購買技術以提高操作效能，又或是知識產權配套服務供應商，你將會從本網站發掘到有用的知識產權貿易資訊。

返回搜索結果

Peptidomimetic Inhibitors for Treatment of Alzheimer's Disease

總結: Researchers at Purdue University have developed a series of novel compounds for beta-secretase inhibition that offer improved pharmacological properties. Novel peptidomimetic scaffolds were utilized to replace conventional hydroxyethylamine isosteres and were shown to be good inhibitors of beta-secretase. This series of compounds shows increased potency, improved aqueous solubility, increased metabolic stability, and improved oral bioavailability over previously identified inhibitors or beta-secretase.

技術優勢: Improved pharmacological propertiesShown to be good inhibitors of beta-secretase

*Background: Alzheimer's disease is a progressive mental deterioration, resulting in loss of memory, confusion and disorientation, and other behavioral problems. Unfortunately, no definitive cure has been developed to treat this disease. Beta-secretase, an important enzyme in the development and onset of Alzheimer's disease, contributes to the formation of amyloid-beta peptides that aggregate in the brain of Alzheimer's patients. Blocking beta-secretase is a potential strategy for the treatment of Alzheimer's disease.

*Web Links: Purdue Office of Technology CommercializationPurdueInnovation and EntrepreneurshipArun GhoshGhosh GroupPurdue Chemistry

欲了解更多信息，請點擊這裡